VSVolker J. J. Schettler

Volker J. J. Schettler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Volker J. J. Schettler has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • P. Grützmacher

    AGAPLESION MVZ Markus Hospital, Frankfurt, Germany

    8 shared publications
  • E. Roeseler

    Center for Nephrology, Hypertension, and Metabolic Diseases, Hanover, Germany

    7 shared publications
  • F. Heigl

    Medical Care Center Kempten-Allgäu, Kempten, Germany

    7 shared publications
  • U. Julius

    Department of Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany

    7 shared publications
  • C. L. Neumann

    BRAVE-Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education e. V, Göttingen, Germany

    5 shared publications
  • R. Klingel

    Apheresis Research Institute, 1st Dept. Internal Medicine University of Mainz, Cologne, Germany

    5 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial

    by Klaus G Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann-Menke, Gunnar H Heine, Hui Cao, Jessica Schorr, Philippe Ferber, Jing Wang, et al.

    Background and Aims: Lipoprotein apheresis (LA) is the only approved treatment for patients with elevated lipoprotein(a) [Lp(a)]. The Lp(a)FRONTIERS APHERESIS trial investigated whether pelacarsen reduces the need for LA in patients from Germany with elevated Lp(a) and established cardiovascular disease (CVD). Methods: Adult patients with Lp(a) levels >60 mg/dl who had undergone ≥35 LA sessions in the prior year were randomized to receive pelacarsen 80 mg or placebo every 4 weeks for 52 weeks. Weekly LA sessions were performed if the Lp(a) measurement from the prior visit was >60 mg/dL. The primary endpoint was the rate of performed LA sessions normalized to the weekly LA schedule (the number of actual LA sessions divided by the number of planned LA sessions during the 52-week period). Secondary endpoints were time to LA avoidance (for ≥24 consecutive weeks) and total LA avoidance from week 12 to week 52. Results: Fifty-one patients were randomized (mean age 61.7 years, mean Lp(a) at baseline 85.4 mg/dL, and mean 44.0 LA sessions in the past 12 months), with 25 of 26 (96.2%) in the pelacarsen arm and 23 of 25 (92.0%) in the placebo arm completing the study. Baseline characteristics were generally balanced between treatment arms. Pelacarsen reduced the mean rates of LA (0.16 vs 0.93 in placebo, odds ratio 0.006, 95% confidence interval [CI] 0.003, 0.013; P < .0001) and substantially increased the hazard of achieving LA avoidance (hazard ratio: 88.3; P = .0014; median time to achieve LA avoidance: 6.1 weeks) and total LA avoidance (odds ratio: 163.2; P = .0005). The placebo-adjusted Lp(a) change from baseline at week 52 was −72% (95% CI: −79%, −61%; P < .0001). Treatment emergent adverse events were similar between arms, except for mostly mild injection site erythema (pelacarsen 38.5%; placebo 0%). Conclusions: Pelacarsen is a highly effective and well-tolerated Lp(a)-targeted therapy that substantially reduces the need for LA in patients with elevated Lp(a) and established CVD. ClinicalTrials.gov, identifier: NCT05305664.


  • Open Access

    Therapeutische Apherese

    by Marion Haubitz, Volker J. J. Schettler, Steffen Mitzner

  • Ist Lipoprotein(a) ein Scheinriese im kardiovaskulären Risikoprofil?

    by Volker J. J. Schettler

    Lipoprotein(a) (Lp(a)) ist ein stark proatherogenes Lipoproteinpartikel, das in hohen Konzentrationen im Blut von Personen gefunden werden kann, welche die Lp(a)-erhöhenden genetischen Varianten geerbt haben 1. Genetisch bedingte hohe oder sehr hohe Lp(a)-Konzentrationen sind somit bei ca. 20 % der überwiegend kaukasischen Allgemeinbevölkerung in Europa vorhanden 1. Eine Reihe groß angelegter Mendelscher Randomisierungsstudien, die in den letzten 15 Jahren veröffentlicht wurden, haben eine starke, lineare und wahrscheinlich kausale Wirkung von Lp(a) auf ein breites Spektrum von Herz-Kreislauf- und Herzklappen-Erkrankungen wie koronare Herzkrankheit (KHK), periphere Herzkrankheit (PAVK) und Aortenklappenstenose sowie eine negative Auswirkung auf die Gesamt- und kardiovaskuläre Sterblichkeit gezeigt 2.

  • The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report

    by V.J.J. Schettler, N. Selke, S. Jenke, T. Zimmermann, G. Schlieper, W. Bernhardt, F. Heigl, P. Grützmacher, I. Löhlein, R. Klingel, et al.


  • Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: Exosomes apheresis

    by Sophie Schröder, Robert Epple, Andre Fischer, Volker J. J. Schettler

    Introduction: Extracellular vesicles (EVs) have been identified as playing a role in atherosclerosis.Methods: A group of 37 hypercholesterolemic patients with atherosclerotic cardiovascular diseases (ASCVD) and 9 patients requiring hemodialysis (HD) were selected for the study.Results: EVs were comparably reduced by various LA methods (Thermo: 87.66% ± 3.64, DALI: 87.96% ± 4.81, H.E.L.P.: 83.38% ± 11.98; represented as SEM). However, LDL‐C (66%; 55%; 75%) and Lp(a) (72%; 67%; 79%) were less effectively reduced by DALI. There was no significant difference in the reduction of EVs when comparing different techniques, such as hemoperfusion (DALI; n = 13), a precipitation (H.E.L.P.; n = 5), and a double filtration procedure (Thermofiltration; n = 19). Additionally, no effect of hemodialysis on EVs reduction was found.Conclusions: The study suggests that EVs can be effectively removed by various LA procedures, and this effect appears to be independent of the specific LA procedure used, as compared to hemodialysis.


  • Open Access

    Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study

    by Michael Lehrke, Anja Vogt, Volker Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N. Dhalwani, Kausik K. Ray

    Introduction Low-density lipoprotein cholesterol (LDL-C) is among the most important modifiable risk factors for cardiovascular disease. In very high-risk patients, the European Society of Cardiology/European Atherosclerosis Society guidelines recommend attaining LDL-C < 55 mg/dL. In the German cohort of the observational HEYMANS study, we aimed to describe the clinical characteristics and LDL-C control among patients initiating evolocumab. Methods Data was collected between 09/2016 and 05/2021 for ≤ 6 months before (retrospectively) and ≤ 30 months after evolocumab initiation (prospectively). Patient characteristics, lipid-lowering therapy (LLT), lipid values, evolocumab use, and safety were collected. Results Of 380 enrolled patients, 93% received evolocumab in secondary prevention and 69% had a history of statin intolerance. At study baseline, 49% did not receive any statins and LDL-C was very high (145 mg/dL). Use of evolocumab decreased LDL-C by a median of 53% within 3 months and remained stable thereafter, despite mainly unchanged background LLT. Overall, 59% attained an LDL-C level < 55 mg/dL (69% with, 49% without LLT). Persistence to evolocumab was 90.6% in months 1–12 and 93.5% in months 13–30. Adverse drug reactions were reported in 8% of patients. Conclusion Data from the German HEYMANS cohort corroborate previous reports on evolocumab effectiveness and safety in clinical practice. Evolocumab initiation was associated with a rapid and sustained LDL-C reduction. Persistence with evolocumab was high. Our finding that patients receiving an evolocumab/LLT combination are more likely to attain the LDL-C goal than those receiving evolocumab alone corroborates previous data showing the importance of using highly intensive therapy. Graphical abstract available for this article. Trial Registration ClinicalTrials.gov Identifier NCT02770131 (registration date 27 April 2016). Graphical Abstract


  • Triangel oder Mahler-Hammer im Konzert von kardiovaskulären Risikofaktoren

    by Volker J. J. Schettler

    Wer einmal die 6. Sinfonie (1903/1904) von Gustav Mahler hört, wird sicherlich im 4. Satz dieses Musikstückes durch den Hammerschlag regelrecht erschüttert werden. Im Gegensatz dazu wirkt eine Triangel geradezu minimalistisch in der Dynamik dieses Musikstückes. Übertragen auf das Lipoprotein(a) (Lp(a)) bleibt es weiterhin unklar, wie ausgeprägt dieser Partikel bei jedem einzelnen Patienten atherosklerotische kardiovaskuläre Erkrankungen (ASCVD) induzieren kann bzw. wie ausgeprägt seine Rolle in der Pathogenese der Atherosklerose („atherosklerotisches Konzert“) tatsächlich ist. Article published online: 06 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Therapeutische Apherese

    by Volker J. J. Schettler

    Trotz neuer Entwicklungen Low-Density-Lipoprotein-Cholesterin (LDL-C) senkender Medikamente wie Statine, Ezetimib sowie Inhibitoren von Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) wie die PCSK9-Antikörper Alirocumab und Evolocumab oder die PCSK9-Antisense-Therapie mit Inclisiran, besteht weiterhin für bestimmte Patienten die Indikation zur Lipoproteinapherese (LA), wenn alle Lebensstil- und medikamentösen Maßnahmen ausgeschöpft wurden (Ultima-Ratio-Therapie) [1]. Als Entscheidungsgrundlage für die Indikation zur LA gilt die Richtlinie Methoden vertragsärztliche Versorgung, Anlage I Nr. 1: Ambulante Durchführung der Apheresen als extrakorporales Hämotherapieverfahren, Rechtsgrundlage: § 135 Abs. 1 SGB V, Gültigkeit: seit 01.01.1991, zuletzt geändert zum: 06.03.2015. Article published online: 13 October 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • LDL-C-Senkung bei Dialysepatienten

    by Volker J.J. Schettler

    ZUSAMMENFASSUNG: Patienten, die aufgrund einer schweren Nierenerkrankung auf eine Dialyse angewiesen sind, haben ein hohes Risiko für Herz-Kreislauf-Erkrankungen. Häufig leiden diese Patienten u. a. auch an Bluthochdruck, Fettstoffwechselstörungen oder Diabetes mellitus. Ob aber in diesem Zusammenhang die Behandlung von Dialysepatienten mit Statinen gerechtfertigt ist, ist weiterhin umstritten, da in der Vergangenheit randomisierte Studien bei diesen Patienten deren Nutzen nicht belegen konnten. Ein differenzierter Blick zeigt jedoch, dass diese Frage nicht einfach zu beantworten ist. Entgegen dem Anschein gibt es Hinweise, dass selbst Dialysepatienten noch unter bestimmten Voraussetzungen von der Therapie mit Statinen oder anderen lipidsenkenden Maßnahmen zu profitieren scheinen.